Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth for both Revuforj and Niktimvo, with positive physician and patient feedback. The company expects profitability with existing resources and stable expenses. The Q&A section provides confidence in FDA approval and market expansion, particularly with the NPM1 label expansion. Although management avoided specific guidance, the overall sentiment is positive with strong financial performance and optimistic future outlooks.
Key Financial Performance
Combined net product sales (Revuforj and Niktimvo) Nearly $100 million in the first half of 2025, significantly exceeding expectations.
Revuforj net revenue $28.6 million in Q2 2025, a 43% quarter-over-quarter increase. Growth attributed to strong uptake, high unmet medical need, and physician enthusiasm.
Niktimvo net revenue $36.2 million in Q2 2025, up from $13.6 million in the first 2 months of Q1. Growth attributed to strong demand and positive physician and patient feedback.
Niktimvo collaboration revenue to Syndax $9.4 million in Q2 2025. Niktimvo is already profitable to Syndax.
R&D expense $62.2 million in Q2 2025, increased due to ongoing trials and commercialization support.
SG&A expense $43.8 million in Q2 2025, increased due to U.S. commercial launch of Revuforj.
Cash, equivalents, and investments $518 million as of June 30, 2025. Expected to support profitability without additional funding.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revuforj and Niktimvo sales: Combined net product sales reached nearly $100 million in the first half of 2025, exceeding expectations. Revuforj net revenue increased 43% quarter-over-quarter to $28.6 million.
Revuforj FDA approval: Revuforj is the first and only FDA-approved treatment for relapsed or refractory acute leukemia with a KMT2A translocation.
Niktimvo launch: Niktimvo generated $36.2 million in net revenue in Q2 2025, up from $13.6 million in Q1.
Market opportunity for Revuforj: The combined market opportunity for Revuforj and Niktimvo exceeds $10 billion. Revuforj's U.S. relapsed/refractory market opportunity is $2 billion, with potential expansion to a $5 billion frontline market.
Market opportunity for Niktimvo: Niktimvo targets a $2 billion total addressable market in third-line chronic GVHD treatments.
Operational efficiency: Operating expenses are expected to remain stable over the next few years, while fully funding strategic priorities. Syndax expects to reach profitability with current funds on hand.
Patient identification and treatment: Over 500 patients have been treated with Revuforj since launch, with 90% of usage in KMT2A patients. Revuforj is increasingly used in earlier lines of therapy, improving outcomes.
Strategic leadership in menin space: Syndax aims to expand Revuforj into earlier lines of therapy and additional patient populations, including frontline settings.
Niktimvo development: Niktimvo is being developed for additional patient populations and diseases, including idiopathic pulmonary fibrosis (IPF).
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company is awaiting FDA approval for its supplemental new drug application (sNDA) for Revuforj in relapsed/refractory mutant NPM1 AML. Any delays or rejections could impact the expansion of their addressable market and revenue projections.
Market Competition: Revuforj and Niktimvo face potential competition from 'me-too' competitors and other targeted therapies in their respective markets. This could impact market share and revenue growth.
Supply Chain and Manufacturing Risks: The company did not explicitly mention supply chain issues, but any disruptions in manufacturing or distribution could impact product availability and sales.
Economic and Market Conditions: Economic uncertainties or changes in healthcare reimbursement policies could affect the affordability and accessibility of the company's therapies, impacting sales.
Clinical Trial Risks: Ongoing and planned clinical trials for Revuforj and Niktimvo in new indications and earlier lines of therapy carry risks of failure or delays, which could hinder market expansion and revenue growth.
Physician and Patient Adoption: While initial adoption of Revuforj and Niktimvo has been strong, sustained growth depends on continued physician and patient acceptance, which could be influenced by emerging data or competitive products.
Financial Risks: The company is relying on its current cash reserves and revenue from two products to achieve profitability. Any underperformance in sales or unexpected expenses could strain financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects quarterly revenue growth to accelerate meaningfully over the next year, driven by the potential approval of Revuforj in NPM1 and longer treatment durations in KMT2Ar acute leukemia.
Revuforj Expansion: Revuforj is expected to expand into relapsed/refractory mutant NPM1 AML, pending FDA approval of the sNDA with a PDUFA action date of October 25, 2025. This expansion could increase the U.S. market opportunity to $2 billion.
Frontline Market Opportunity: The company is extending its leadership position into the frontline setting for acute leukemia, a U.S. market opportunity exceeding $5 billion. Enrollment is ongoing in pivotal trials for patients unfit for intensive chemotherapy, with additional trials for fit patients expected to start in Q4 2025.
Niktimvo Growth: Niktimvo is poised for further growth in the $2 billion third-line chronic GVHD market. The company anticipates long-term patient retention on therapy due to the chronic nature of the disease and the drug's tolerability.
Profitability Outlook: Syndax expects to achieve sustained profitability with current funds on hand, driven by increasing cash flow contributions from Revuforj and Niktimvo alongside a stable operating expense base.
Pipeline Development: The company is advancing trials for Revuforj in newly diagnosed fit and unfit acute leukemia patients, as well as for Niktimvo in earlier lines of chronic GVHD therapy and idiopathic pulmonary fibrosis (IPF).
Market Penetration: Revuforj aims to penetrate 50% of the annual 2,000 patient incidence for KMT2A acute leukemia by the end of 2025, with increasing use in earlier treatment lines and post-transplant settings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the assumptions for achieving profitability with Revuforj and Niktimvo?
A:The company expects to achieve profitability with existing resources and stable operating expenses over the next 2-3 years. Profitability is expected to be achieved on relapsed/refractory indications alone, without relying on frontline expansion. Both product launches are outperforming expectations.
Q:What is the typical timeline for patients moving to transplant after starting treatment?
A:Patients typically respond to Revuforj within the first few cycles (2-3 cycles) and move to transplant shortly thereafter, often within a couple of weeks. About 1/3 of patients have moved to transplant, and this number is expected to increase as patients are treated earlier in the treatment paradigm.
Q:What is the observed treatment duration for Revuforj in real-world practice?
A:The average treatment duration in the first year is 4-6 months, with earlier line patients expected to have longer durations. By 2026, the average treatment duration is expected to be 6-12 months, skewing towards the latter end as the launch matures.
Q:What is the guidance for operating expenses for the rest of the year?
A:Operating expenses (excluding noncash stock compensation) are expected to be $95-100 million for Q3 and $370-390 million for the full year. Q4 expenses are expected to be similar to Q3.
Q:What is the penetration rate for KMT2A patients and expectations for growth?
A:The company has treated over 500 patients since launch, covering about 25% of the 2,000 KMT2A relapsed/refractory AML and ALL patients. They expect to reach 50% penetration by the end of the year and see further growth potential beyond that.
Q:What is the status of the NPM1 label expansion and its impact?
A:The company has submitted data to guidelines and expects updates before the approval of NPM1. The expansion is expected to significantly increase the patient population from 2,000 to 6,000, driving growth starting at the end of the year and into the next year.
Q:What is the progress and confidence level regarding the FDA approval for NPM1?
A:The submission is progressing well with consistent quality dialogue with the FDA. The company has a PDUFA date of October 25th and is prepared for launch, with no indications of issues.
Q:What are the expectations for the BEAT AML study and intensive chemo combo?
A:The BEAT AML study showed high CR and MRD negativity rates (67% and 100%, respectively). Median OS is expected to improve with longer follow-up. For the intensive chemo combo, CR and MRD negativity are key benchmarks, and updates are expected later this year.
Q:What is the expectation for patients restarting Revuforj after transplant?
A:About 1/3 of patients have restarted Revuforj post-transplant, and the majority of the remaining 2/3 are expected to restart as well. Reimbursement for restarting is seamless, with no challenges reported.
Q:What is the preparation for the NPM1 label expansion launch?
A:The company is leveraging its experience with KMT2A, maintaining strong relationships with treatment centers, and emphasizing the efficacy of Revuforj. A significant uptake is expected upon approval, with the patient population increasing to 6,000.
Q:What is the potential for Niktimvo in IPF?
A:The IPF market has about 150,000 patients in the U.S. and 280,000 worldwide. The company is conducting a Phase II trial, expecting to complete enrollment this year and report data next year. The drug is expected to differentiate itself in a market dominated by generics.
Q:What is the expected duration of maintenance therapy for Revuforj post-transplant?
A:Physicians expect patients to stay on maintenance therapy for 1-2 years, with some patients potentially staying on indefinitely to prevent relapse.
Q:Review of Unclear Management Responses
A:Management avoided providing direct revenue guidance for Revuforj and Niktimvo, instead emphasizing stable operating expenses and outperforming launches. They also did not specify peak penetration rates for KMT2A or provide exact percentages for maintenance therapy uptake post-transplant.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AUGMENT
Chief Medical
Dr
EHA
Incyte
LLC Research
MRD negativity
Medical Officer
NPM AML
NUPr
Research Division
Revuforj patient
Slide
Tier
activity
axatilimab
benchmark
cash flow
contribution
driver
enrollment
expense base
franchise
increase
indicator
opportunity Revuforj
patient NPM
patient Revuforj
patient therapy
patient transplant
percentage
presentation
rate patient
remission
response rate
subtypes
survival month
use line
ven aza
SNDX Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Positive4-30
Syndax Pharmaceuticals reported a strong financial performance with a 224% year-over-year revenue increase, driven by demand for Revuforj and Niktimvo. The Q&A highlighted positive market dynamics, such as high investigator interest in Niktimvo for IPF and potential market leadership for Revuforj. Despite some uncertainties in guidance, the overall sentiment is positive due to strong revenue growth, promising pipeline developments, and robust financial health, suggesting a positive stock price movement.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance with revenue and net income growth, a focus on strategic initiatives, and positive market trends in oncology. Although no specific risks were discussed, the company's optimistic outlook on revenue expectations and strategic partnerships suggests a positive sentiment. The market cap of $1.7 billion indicates moderate sensitivity to these factors, leading to a positive prediction for stock movement in the short term.
SNDX Slides
SNDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
